Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are incretin mimetics that both stimulate glucose-dependent insulin release and suppress glucagon secretion, leading to reduced blood glucose levels without affecting defence mechanisms to hypoglycaemia. The gene discussed is INS; the disease is Hypoglycemia.